Sumitomo Mitsui Trust Group’s CRISPR Therapeutics CRSP Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$88.2M	Sell	1,853,875 -104,236	-5%	-$5.5M	0.06%	306
2025 Q4	$103M	Sell	1,958,111 -205,564	-10%	-$12.3M	0.06%	283
2025 Q3	$140M	Sell	2,163,675 -251,163	-10%	-$14.4M	0.08%	227
2025 Q2	$117M	Sell	2,414,838 -125,051	-5%	-$4.84M	0.07%	253
2025 Q1	$86.4M	Sell	2,539,889 -205,787	-7%	-$8.72M	0.06%	311
2024 Q4	$108M	Sell	2,745,676 -222,358	-7%	-$10.5M	0.07%	262
2024 Q3	$139M	Sell	2,968,034 -183,480	-6%	-$9.31M	0.1%	204
2024 Q2	$170M	Sell	3,151,514 -117,271	-4%	-$6.78M	0.13%	161
2024 Q1	$223M	Sell	3,268,785 -100,977	-3%	-$7.23M	0.15%	145
2023 Q4	$211M	Sell	3,369,762 -95,708	-3%	-$5.29M	0.16%	145
2023 Q3	$157M	Sell	3,465,470 -67,887	-2%	-$3.51M	0.13%	167
2023 Q2	$198M	Sell	3,533,357 -439,823	-11%	-$25M	0.15%	141
2023 Q1	$180M	Sell	3,973,180 -33,296	-0.8%	-$1.62M	0.13%	169
2022 Q4	$163M	Sell	4,006,476 -256,260	-6%	-$13.6M	0.13%	182
2022 Q3	$279M	Sell	4,262,736 -321,362	-7%	-$23.3M	0.23%	100
2022 Q2	$279M	Sell	4,584,098 -35,649	-0.8%	-$2.1M	0.21%	98
2022 Q1	$290M	Buy	+4,619,747	New	+$290M	0.19%	113

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group's CRSP Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group reduced its CRISPR Therapeutics (CRSP) stake by 5.3% in Q1 2026, selling an estimated $5.5M and leaving 1,853,875 shares worth $88.2M. The position accounts for 0.06% of the portfolio, ranked #306.

Sumitomo Mitsui Trust Group first reported a position in CRSP in Q1 2022 and has held it in 17 quarters since. The position peaked at $290M in Q1 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Sumitomo Mitsui Trust Group held 1,853,875 shares of CRISPR Therapeutics worth $88.2M as of Q1 2026.
Sumitomo Mitsui Trust Group sold 104,236 CRISPR Therapeutics shares in Q1 2026, an estimated $5.5M.
CRISPR Therapeutics made up 0.06% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #306 holding.
Sumitomo Mitsui Trust Group first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 17 quarters since.
Sumitomo Mitsui Trust Group's CRISPR Therapeutics position peaked at $290M in Q1 2022.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.